BB Liquidatin a Aktie
WKN: 924821 / ISIN: US0936791088
14.06.2024 11:50:00
|
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Novo Nordisk's (NYSE: NVO) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024. But note the use of the word "currently." Wegovy's market-topping position is precarious. Here are three drugs most likely to dethrone Novo Nordisk's blockbuster drug.Eli Lilly (NYSE: LLY) won U.S. regulatory approval for Zepbound in helping patients lose weight in November 2023. In the first quarter of 2024, the sales for Lilly's obesity drug topped $517 million. Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!